These results confirmed functional results establishing a cross-talk between integrins and EGFR in several tumors, including gliomas [32,62], and raised the possibility that for EGFR- and integrin α5β1-positive patients, combined therapies based on the dual inhibition of both receptors might be of interest. This evidence concerns the gene EGFR and central nervous system cancer.